Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.57 |
| ▸ | ADA | P00813 | 1/20 | 0.53 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28121858 | 0.92 | AHCY (0.56) | AHCYADASTING1POLBTP53 | |
| SCHEMBL9875644 | 0.92 | AHCY (0.56) | AHCYADASTING1POLBTP53 | |
| SCHEMBL4451661 | 0.92 | AHCY (0.59) | AHCYADASTING1POLBTP53 | |
| SCHEMBL9875640 | 0.92 | AHCY (0.56) | AHCYADASTING1POLBTP53 | |
| SCHEMBL29375190 | 0.91 | AHCY (0.55) | AHCYADASTING1POLBTP53 | |
| SCHEMBL2505364 | 0.91 | AHCY (0.55) | AHCYADASTING1POLBTP53 | |
| SCHEMBL28939795 | 0.91 | AHCY (0.55) | AHCYADASTING1POLBTP53 | |
| SCHEMBL29739820 | 0.91 | AHCY (0.55) | AHCYADASTING1POLBTP53 | |
| SCHEMBL30358148 | 0.90 | AHCY (0.52) | AHCYADASTING1POLBTP53 | |
| SCHEMBL7192503 | 0.90 | AHCY (0.52) | AHCYADASTING1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2117 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711364-A1 | FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND | Pharmaengine, Inc. (TW) | 2026-03-18 | — | — | EP | claimed |
| EP-4701737-A2 | MTA-COOPERATIVE PRMT5 INHIBITOR | Pharmaengine, Inc. (TW) | 2026-03-04 | — | — | EP | claimed |
| WO-2025077721-A1 | MYT1 INHIBITOR BASED ON FUSED THIAZOLE OR PYRIDINE RING | PHARMAENGINE, INC. (CN) | 2025-04-17 | — | — | WO | claimed |
| CN-119798282-A | Fused pyridine ring-based Myt1 inhibitors | 智擎生技制药股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2024222914-A2 | MTA-COOPERATIVE PRMT5 INHIBITOR | PHARMAENGINE, INC. (CN) | 2024-10-31 | — | — | WO | claimed |
| WO-2023130012-A1 | COMPOUNDS FOR MUTANT KRAS PROTEIN DEGRADATION AND USES THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2023-07-06 | — | — | WO | claimed |
| EP-3544685-B1 | HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF | DEV CT BIOTECHNOLOGY (TW) | 2023-01-04 | — | — | EP | claimed |
| EP-3411036-B1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE INC (TW) | 2021-12-29 | — | — | EP | claimed |
| EP-3925625-A1 | HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE | ANP Technologies, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2021222138-A1 | COMPOUNDS FOR MUTANT RAS PROTEIN DEGRADATION | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2021-11-04 | — | — | WO | claimed |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | SANTARIS PHARMA A/S | 2004-12-02 | — | — | US | claimed |
| WO-2004083430-A2 | SHORT INTERFERING RNA (siRNA) ANALOGUES | SANTARIS PHARMA A/S (DK) | 2004-09-30 | — | — | WO | claimed |
| WO-2004069992-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | claimed |
| WO-2004069991-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | claimed |
| WO-2004069990-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | claimed |
| US-20040138140-A1 | Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy | TELIK, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004045593-A2 | COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY | TELIK, INC. (US) | 2004-06-03 | — | — | WO | claimed |
| WO-2004020468-A2 | INTERFERON BETA-LIKE MOLECULES FOR TREATMENT OF CANCER | MAXYGEN APS (DK) | 2004-03-11 | — | — | WO | claimed |
| WO-2003061703-A9 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS WITH STATINS | NOVIMMUNE SA (CH) | 2003-12-24 | — | — | WO | claimed |
| WO-1996005865-A1 | COMBINATION IMMUNOTOXIN/ANTINEOPLASTIC AGENT THERAPY FOR B-LINEAGE CANCER | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-02-29 | — | — | WO | claimed |